Clinical Program
Race is progressing a robust pipeline of clinical activities for RC220 bisantrene.
RC220 is a proprietary formulation designed to enable peripheral and central intravenous administration of bisantrene.

Preclinical Activities
Continue studies to determine the cardioprotection mechanism of action
Develop the next generation bisantrene with a focus on the m6A RNA opportunity
Continue build of the preclinical data package needed to support pharma transaction/partnering activities
Generate data to enable an FDA IND application